Professor of Medicine, Duke University
Verified email at
Cited by
Cited by
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
KD Miller, LI Chap, FA Holmes, MA Cobleigh, PK Marcom, ...
Journal of clinical oncology 23 (4), 792-799, 2005
Whole-genome analysis informs breast cancer response to aromatase inhibition
MJ Ellis, L Ding, D Shen, J Luo, VJ Suman, JW Wallis, BA Van Tine, ...
Nature 486 (7403), 353-360, 2012
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression
CK Anders, DS Hsu, G Broadwater, CR Acharya, JA Foekens, Y Zhang, ...
Journal of clinical oncology 26 (20), 3324-3330, 2008
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in …
HA Burris III, HI Hurwitz, EC Dees, A Dowlati, KL Blackwell, B O'Neil, ...
Journal of clinical oncology 23 (23), 5305-5313, 2005
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to …
AD Seidman, D Berry, C Cirrincione, L Harris, H Muss, PK Marcom, ...
Journal of Clinical Oncology 26 (10), 1642-1649, 2008
Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers
AJ Armstrong, MS Marengo, S Oltean, G Kemeny, RL Bitting, JD Turnbull, ...
Molecular cancer research 9 (8), 997-1007, 2011
Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy
W Demark-Wahnefried, BL Peterson, EP Winer, L Marks, N Aziz, ...
Journal of clinical oncology 19 (9), 2381-2389, 2001
Breast cancer
RW Carlson, DC Allred, BO Anderson, HJ Burstein, WB Carter, SB Edge, ...
Journal of the National Comprehensive Cancer Network 7 (2), 122-192, 2009
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
SM Tolaney, WT Barry, CT Dang, DA Yardley, B Moy, PK Marcom, ...
New England Journal of Medicine 372 (2), 134-141, 2015
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor–rich stage 2 to 3 breast cancer …
MJ Ellis, VJ Suman, J Hoog, L Lin, J Snider, A Prat, JS Parker, J Luo, ...
Journal of Clinical Oncology 29 (17), 2342, 2011
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
LA Carey, HS Rugo, PK Marcom, EL Mayer, FJ Esteva, CX Ma, MC Liu, ...
Journal of clinical oncology 30 (21), 2615, 2012
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
NL Spector, W Xia, H Burris III, H Hurwitz, EC Dees, A Dowlati, B O'Neil, ...
Journal of clinical oncology 23 (11), 2502-2512, 2005
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor …
HJ Burstein, LN Harris, PK Marcom, R Lambert-Falls, K Havlin, ...
Journal of clinical oncology 21 (15), 2889-2895, 2003
Cancer Yield of Mammography, MR, and US in High-Risk Women: Prospective Multi-Institution Breast Cancer Screening Study1
CD Lehman, C Isaacs, MD Schnall, ED Pisano, SM Ascher, PT Weatherall, ...
Radiology 244 (2), 381-388, 2007
Genetic/familial high-risk assessment: breast and ovarian
MB Daly, JE Axilbund, S Buys, B Crawford, CD Farrell, S Friedman, ...
Journal of the National Comprehensive Cancer Network 8 (5), 562-594, 2010
Lower-dose vs high-dose oral estradiol therapy of hormone receptor–positive, aromatase inhibitor–resistant advanced breast cancer: A phase 2 randomized study
MJ Ellis, F Gao, F Dehdashti, DB Jeffe, PK Marcom, LA Carey, MN Dickler, ...
Jama 302 (7), 774-780, 2009
Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology
WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ...
Journal of the National Comprehensive Cancer Network 14 (3), 324-354, 2016
Breast cancer version 2.2015
WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ...
Journal of the National Comprehensive Cancer Network 13 (4), 448-475, 2015
Genetic/familial high-risk assessment: breast and ovarian, version 2.2015
MB Daly, R Pilarski, JE Axilbund, M Berry, SS Buys, B Crawford, M Farmer, ...
Journal of the National Comprehensive Cancer Network 14 (2), 153-162, 2016
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study
HJ Burstein, A Keshaviah, AD Baron, RD Hart, R Lambert‐Falls, ...
Cancer 110 (5), 965-972, 2007
The system can't perform the operation now. Try again later.
Articles 1–20